Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How do you choose between darolutamide and abiraterone when adding to docetaxel plus ADT in management of castrate sensitive high burden metastatic prostate cancer?
Related Questions
What are your top takeaways from ASCO GU 2025?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
Is there any evidence that ivermectin suppresses the PSA level in prostate cancer?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
